Cargando…
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease. Treatment is only effective when received at the early stages of the disease and it involved two drugs (nifurtimox (NF...
Autores principales: | Rolon, Miriam, Hanna, Eustine, Vega, Celeste, Coronel, Cathia, Dea-Ayuela, Maria Auxiliadora, Serrano, Dolores R., Lalatsa, Aikaterini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504116/ https://www.ncbi.nlm.nih.gov/pubmed/36145570 http://dx.doi.org/10.3390/pharmaceutics14091822 |
Ejemplares similares
-
Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020) -
Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009) -
Microfluidic Manufacture of Lipid-Based Nanomedicines
por: Osouli-Bostanabad, Karim, et al.
Publicado: (2022) -
Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016) -
Engineering 3D Printed Microfluidic Chips for the Fabrication of Nanomedicines
por: Kara, Aytug, et al.
Publicado: (2021)